NK-92

An interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma.

Cell Type:
Natural Killer (NK)
Tissue Origin:
blood
Species:
human
Research Area:
Immunotherapy / Hematology
Cell Characteristics:
Suspension

Recommended Media

RPMI-1640 medium was developed by Moore et al., at Roswell Park Memorial Institute, hence the acronym RPMI. The formulation is based on the RPMI-1630 series of media utilizing a bicarbonate buffering system and alterations in the amounts of amino acids and vitamins. RPMI-1640 medium has been used for the culture of human normal and neoplastic leukocytes. RPMI-1640 when properly supplemented, has demonstrated wide applicability for supporting growth of many types of cell cultures, including fresh human lymphocytes in the 72-hour phytohemagglutinin (PHA) stimulation assay.

There are a variety of formulations:
12-702         - with L-glutamine
BE12-702/U1 - with UltraGlutamineI
BE15-702D    - [powder] with L-glutamine
12-167          - without L-glutamine
12-115          - with L-glutamine and 25 mM HEPES buffer
BE12-115/U1 - with UltraGlutamineI and 25 mM HEPES buffer
04-525          - with L-glutamine and 165 nM MOPS (used for some mycological assays)
09-774          - with L-glutamine, 25 mM HEPES buffer 100 units/ml penicillin, 50 ug/ml streptomycin
12-918          - without L-glutamine or phenol red
BE12-752       - with L-glutamine, without D-glucose

Storage = 2ºC to 8ºC 
  (versions without L-glutamine and those with UltraGlutamine can be stored at 15ºC to 30ºC)

MEM Alpha was developed in 1971 and differs from standard MEM by containing the following unique components:  vitamin B12, ascorbic acid, non-essential amino acids, sodium pyruvate, lipoic acid, and D-biotin.
This media has been used to culture bone marrow cells and amniotic cells for chromosome analysis.

MEM Alpha is available as:
12-169 - without L-glutamine, deoxyribonucleosides or ribonucleosides
BE02-002 - with Ultraglutamine, deoxyribonucleosides and ribonucleosides

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
R A-024 5e6 16-34% 30-50% Plasmid (general) 2 µg 100 µl I/II/2b
SE CA-137 2e6 45.2% 71.9% Plasmid (general) 2 µg 100 µl 4D X-Unit

Citations

Categories:
Serum-free and Speciality Media 
Authors:
Nowakowska P, Romanski A, Miller N, Odendahl M, Bonig H, Zhang C, Seifried E, Wels WS, Tonn T 
In:
Cancer Immunol Immunother (2018) 67 (1): 25-38 
Categories:
Serum-free and Speciality Media 
Authors:
Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS.  
In:
Mol Ther (2015) 23 (2): 330-8 
Categories:
Transfection 
Authors:
Schoenborn JR, Dorschner MO, Sekimata M, Santer DM, Shnyreva M, Fitzpatrick DR, Stamatoyonnapoulos JA, Wilson CB 
In:
Nat Immunol (2007) 8(7): 732-42 
Categories:
Transfection 
Authors:
Chen X, Trivedi PP, Ge B, Krzewski K, Strominger JL 
In:
Proc Natl Acad Sci USA (2007) 104(15): 6329-34 
Categories:
Transfection 
Authors:
Huang C, Bi E, Hu Y, Deng W, Tian Z, Dong C, Hu Y, Sun B 
In:
J Immunol (2006) 176(7): 4173-81 
Categories:
Live Cell Imaging 
Authors:
Wagner J1, Kline CL1, Zhou L1, Campbell KS2, MacFarlane AW2, Olszanski AJ3, Cai KQ4, Hensley HH5, Ross EA6, Ralff MD1, Zloza A7, Chesson CB7, Newman JH7, Kaufman H7, Bertino J7, Stein M7, El-Deiry WS1 
In:
J Clin Invest () 6: 2325-2338